Denver-based biotechnology startup Pluto Bio has secured $3.6 million in a funding round led by Kickstart, with participation from existing investors Silverton Partners and angel investors.
This funding will help expand the company’s AI-driven multi-omics analysis platform, aiming to revolutionize drug discovery and biological data analysis.
AI-Driven Platform Boosts Pluto Bio’s Drug Development Potential
Pluto Bio’s platform enables scientists to analyze complex biological data, run bioinformatics pipelines, and generate publishable visualizations without needing coding expertise.
By providing data driven tools to pharmaceutical companies, the platform contributes significantly to target discovery, biomarker identification, and translational medicine, thereby enhancing the drug development process.
This investment will allow Pluto Bio to further develop its AI-powered solutions, increase integrations with other research tools, and create commercial roles to expand distribution into new therapeutic areas.
The platform is already in use by mid and large sized pharmaceutical companies across North America and Europe, playing a key role in discovery biology, translational research, and computational research teams.
With this new funding, Pluto Bio aims to further its mission of making biological data more accessible and understandable, enabling scientists to gain faster and more reliable insights.
